• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

SynVantage  

AI-enhanced relay-based drug discovery for optimizing Design-Make-Test-Analyze (DMTA) cycle

SynVantage is Syngene’s platform that enables a continuous and seamless transition between different stages of the Design-Make-Test-Analyze (DMTA) cycle in drug discovery.
The process ensures a relay-based changeover between scientists and other support functions who may be working in shifts in the laboratories at any stage in the drug discovery cycle.

Relay-based approach

In a relay-based model, the ownership for a discovery program lies collectively with a team of scientists. They work collaboratively in a round-the-clock shift system with a just-in-time approach, thereby eliminating inefficiencies and waste. For example, in a small molecule discovery program based on the relay-based model, a team of chemists would work in a coordinated, tandem manner on each chemical reaction step within a synthetic scheme – reagent procurement to reaction set-up, monitoring, and workup, purification, and characterization.

The 24/7 or 24/5 relay model can be configured to cover all three work shifts on a working day with efficient planning and operations. Further, a team leader assigned to this model would ensure seamless handover between two scientists in two different shifts.

Accelerating drug discovery cycle with SynVantage

We believe that our 24/7 or 24/5 relay-based discovery can significantly reduce early discovery timelines by 12 to 18 months, depending on the type of project being handled.
Supporting SynVantage in this task are AI-based predictive algorithms that rapidly and accurately understand the patterns and molecular changes required to predict the optimal compound.  This in turn, would result in:

  • Optimal utilization of resources
  • Faster response to emerging needs for therapeutic discovery
  • Faster time-to-market in bringing new therapies to patients in need

SynVantage can be used across Syngene’s drug discovery offerings of Chemistry, Biology, Safety Assessment, and Research Informatics. All the support functions at Syngene like procurement and stores, purification, analysis, EHS, administration, IT, HR, and operations have also been enabled to complement the relay model.

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details